Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Nov 16, 2023 11:42am
133 Views
Post# 35739282

RE:RE:RE:RE: Novartis and Legend Biotech Sign Exclusive License Agreemen

RE:RE:RE:RE: Novartis and Legend Biotech Sign Exclusive License Agreemen
I thought we were supposed to have a CarT deal 2 years ago or at least that was the expectations and just how long does it take to reproduce mice results given that companies supposedly signed mta's a long time ago to try to reproduce the said results. As for Andrew, nice guy but has yet to prove himself to shareholders. The company cannot really change directions on anything now, they just need to get their act together and get a deal done and any delay better not be for one's glory especially if they are turning down the possiblitly of a BO at what shareholders might think is a reasonable deal.
<< Previous
Bullboard Posts
Next >>